IDEAYA enters option/license deal with Biocytogen for B7H3/PTK7 BsADC; total potential $406.5M

IDEAYA Biosciences, Inc.

Total potential payments of $406.5M including $100M development/regulatory milestones and single-digit royalties.
Option for exclusive worldwide license; upfront and option exercise fees up to $6.5M.
Targets B7H3/PTK7 co-expression in lung, colorectal, head and neck cancers with double-digit prevalence.
Development candidate nomination targeted for H2 2024; potential combo with DDR pipeline including IDE161 (PARG).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.